Abstract Library

#4543 Single-cell transcriptomic landscape indicates the potential role of immunotherapy in metastatic pancreatic angiosarcoma

Introduction: Pancreatic angiosarcoma is a rare and highly aggressive tumour originated from lymphatic or vascular endothelial cells, with poor prognosis and few effective treatments. However, little is known about its tumour microenvironment and the mechanisms of its progression.

Conference:

Presenting Author: Yang Y

Authors: Yang Y, Chen L, Liu M, Lin X, Peng S,

Keywords: pancreatic angiosarcoma, single-cell RNA sequencing, immunotherapy, PD-L1, CD86,

#4513 Predictive value of different PD-L1 immunohistochemistry clones for immunotherapy efficacy in neuroendocrine tumours: A case series

Introduction: In the ZS001 clinical trial, we observed that NET patients with higher PD-L1 expression levels were more likely to benefit preferentially from immunotherapy.

Conference:

Presenting Author:

Authors: Sun Y, Zhang Q, Cao F, Huang X, Zhang P,

Keywords: neuroendocrine tumour, immunotherapy, PD-L1, SP142, 28-8, C0148, E1L3N,

#4392 Updated results of first-line chemotherapy combined with an immune checkpoint inhibitor for advanced extrapulmonary neuroendocrine carcinoma: A single arm, phase II study

Introduction: NEC is a rare, aggressive cancer with limited response to standard first-line chemo (etoposide + cisplatin/carboplatin, EP/EC).

Conference:

Presenting Author:

Authors: Cao D, Li X, Li R, Wang X, Yang Y,

Keywords: neuroendocrine carcinoma, First-line, chemotherapy, camrelizumab,

#4285 Predictive biomarkers for immunotherapy efficacy in neuroendocrine neoplasms

Introduction: The application of immunotherapy in NENs is still in its early stages. Identifying reliable predictive biomarkers of efficacy is critical for research, enabling better selection of patients who are more likely to respond to immunotherapy and improving treatment success rates.

Conference:

Presenting Author: Liang Y

Authors: Liang Y, Sun Z, Jia X, Chen J,

Keywords: immunotherapy, biomarker, neuroendocrine neoplasm,

#4125 Durvalumab (D) plus Tremelimumab (T) for the treatment of patients with progressive, advanced medullary thyroid carcinoma (MTC) – DUTHY (GETNE-T1812) trial

Introduction: Evidence for immunotherapy (IT) in patients (pts) with MTC is limited and has shown modest activity.

Conference:

Presenting Author:

Authors: García-Álvarez A, Molina-Cerrillo J, Castelo B, Plana M, Iglesias L,

Keywords: Medullary thyroid carcinoma, Immunotherapy, durvalumab, tremelimumab, anti PD-L1, anti CTLA-4,